                               SEQUENCE LISTING

<110> THE MEDICINES COMPANY
 
<120> METHODS FOR PREVENTING CARDIOVASCULAR EVENTS THROUGH PROPROTEIN 
      CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) PROTEIN REDUCTION

<130> A115-2.WO

<140>
<141>

<150> 62/550,426
<151> 2017-08-25

<150> 62/472,525
<151> 2017-03-16

<150> 62/422,028
<151> 2016-11-14

<150> 62/409,816
<151> 2016-10-18

<160> 4     

<170> PatentIn version 3.5

<210> 1
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 1
acaaaagcaa aacaggucua gaa                                               23


<210> 2
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<220>
<223> Description of Combined DNA/RNA Molecule: Synthetic
      oligonucleotide

<400> 2
cuagaccugu tuugcuuuug u                                                 21


<210> 3
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 3
acaaaagcaa aacaggucua gaa                                               23


<210> 4
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<220>
<223> Description of Combined DNA/RNA Molecule: Synthetic
      oligonucleotide

<400> 4
cuagaccugu tuugcuuuug u                                                 21



